APA (7th ed.) Citation

Gong, J., Lemech, C., Day, D., Shan, J., Morris, M., Nagrial, A., . . . Shen, L. (2024). 576P Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study. Annals of Oncology, 35, S467. https://doi.org/10.1016/j.annonc.2024.08.645

Chicago Style (17th ed.) Citation

Gong, J., et al. "576P Safety and Efficacy of IBI354 (anti-HER2 ADC) in Patients (pts) with Advanced Gastrointestinal (GI) Cancers: Results from a Phase I Study." Annals of Oncology 35 (2024): S467. https://doi.org/10.1016/j.annonc.2024.08.645.

MLA (9th ed.) Citation

Gong, J., et al. "576P Safety and Efficacy of IBI354 (anti-HER2 ADC) in Patients (pts) with Advanced Gastrointestinal (GI) Cancers: Results from a Phase I Study." Annals of Oncology, vol. 35, 2024, p. S467, https://doi.org/10.1016/j.annonc.2024.08.645.